BAY 94-9027 provides effective long-term prophylaxis in pediatric patients: Interim results of the PROTECT VIII Kids extension study

被引：0

作者：

Kenet, Gili ^{[1
]}

Biss, Tina ^{[2
]}

Steele, MacGregor ^{[3
]}

Linardi, Camila ^{[4
]}

Tseneklidou-Stoeter, Despina ^{[5
]}

Saxena, Kapil ^{[4
]}

机构：

[1] Chaim Sheba Med Ctr, Israel Natl Hemophilia Ctr, Tel Hashomer, Israel

[2] Newcastle Upon Tyne Hosp NHS Fdn Trust, Newcastle Upon Tyne, Tyne & Wear, England

[3] Univ Calgary, Alberta Childrens Hosp, Cumming Sch Med, Calgary, AB, Canada

[4] Bayer, Whippany, NJ USA

[5] Bayer, Berlin, Germany

来源：

HAEMOPHILIA | 2018年 / 24卷

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

M-FPMED02-

引用

页码：15 / 15

页数：1

共 50 条

[1] BAY 94-9027 Provides Safe and Effective Long-Term Prophylaxis in Pediatric Patients: Results from the PROTECT VIII Kids Extension Study
Ahuja, Sanjay
Fischer, Kathelijn
Biss, Tina
Enriquez, Monika Maas
Mancuso, Maria-Elisa
Steele, MacGregor
Wang, Maria
Kenet, Gili
[J]. BLOOD, 2020, 136
[2] Safety of long-term prophylaxis with BAY 94-9027: Interim results of >5 years of treatment in the PROTECT VIII extension trial
Reding, Mark T.
Ng, Hen Joo
Tseneklidou-Stoefer, Despina
Linardi, Camila
Lalezari, Shadan
[J]. HAEMOPHILIA, 2018, 24 : 17 - 18
[3] Effective protection for >5 years with bay 94-9027 prophylaxis: interim results from the protect VIII extension trial
Thomson, G.
Holme, P. A.
Wang, M.
Enriquez, M. Maas
[J]. HAEMOPHILIA, 2018, 24 : 114 - 114
[4] BAY 94-9027 PROVIDED EFFECTIVE LONG-TERM PROPHYLAXIS IN PEDIATRIC PATIENTS AGED ≥ 12 YEARS AT THE END OF THE PROTECT VIII KIDS EXTENSION STUDY, INDICATING CONSISTENT SAFETY OF TREATMENT INTO ADOLESCENCE
Ahuja, S.
Fischer, K.
Biss, T.
Enriquez, M. Maas
Mancuso, M. E.
Steele, M.
Wang, M.
Kenet, G.
[J]. HAEMOPHILIA, 2021, 27 : 48 - 48
[5] EFFECTIVE PROPHYLAXIS WITH BAY 94-9027 IN ADOLESCENTS WITH HEMOPHILIA A: RESULTS FROM THE PROTECT VIII MAIN STUDY AND ONGOING EXTENSION
Kerlin, Bryce
Ducore, Jonathan
Ahuja, Sanjay
Afonja, Olubunmi
Saxena, Kapil
[J]. PEDIATRIC BLOOD & CANCER, 2018, 65
[6] PROTECT VIII kids extension study: Long-term safety and efficacy of BAY 94-9027 (damoctocog alfa pegol) in children with severe haemophilia A
Mancuso, Maria Elisa
Biss, Tina
Fischer, Kathelijn
Enriquez, Monika Maas
Steele, MacGregor
Wang, Maria
Tseneklidou-Stoeter, Despina
Ahuja, Sanjay
Kenet, Gili
[J]. HAEMOPHILIA, 2021, 27 (03) : 434 - 444
[7] CONFIRMED SAFETY PROFILE OF BAY 94-9027 PROPHYLAXIS FOR ≥5 YEARS: OUTCOMES FROM THE PROTECT VIII AND PROTECT VIII KIDS EXTENSION STUDIES
Mancuso, M. E.
Holme, P. A.
Kenet, G.
Simpson, M.
Di Minno, M. N. D.
Baumann, A.
Enriquez, Maas M.
Reding, M. T.
[J]. HAEMATOLOGICA, 2021, 106 (09) : 7 - 8
[8] Confirmed long-term safety and efficacy of prophylactic treatment with BAY 94-9027 in severe haemophilia A: final results of the PROTECT VIII extension study
Reding, Mark T.
Pabinger, Ingrid
Holme, Pal Andre
Poulsen, Lone
Negrier, Claude
Chalasani, Pavani
Enriquez, Monika Maas
Wang, Maria
Meijer, Karina
Mancuso, Maria Elisa
Lalezari, Shadan
[J]. HAEMOPHILIA, 2021, 27 (03) : E347 - E356
[9] EFFICACY AND SAFETY OF BAY 94-9027 IS SUSTAINED FOR 5 YEARS: OUTCOMES IN PATIENTS FROM THE PROTECT VIII AND PROTECT VIII KIDS EXTENSION STUDIES
Santagostino, E.
Di Minno, M. N. D.
Lalezari, S.
Kenet, G.
Enriquez, M. Maas
Wang, M.
Reding, M.
[J]. HAEMOPHILIA, 2020, 26 : 73 - 73
[10] BAY 94-9027 prophylaxis is efficacious and well tolerated for up to >5 years with extended dosing intervals: PROTECT VIII extension interim results
Lalezari, Shadan
Reding, Mark T.
Pabinger, Ingrid
Holme, Pal Andre
Negrier, Claude
Chalasani, Pavani
Shin, Ho-Jin
Wang, Maria
Tseneklidou-Stoeter, Despina
Maas Enriquez, Monika
[J]. HAEMOPHILIA, 2019, 25 (06) : 1011 - 1019

← 1 2 3 4 5 →